摘要
目的:研究比较普罗帕酮与胺碘酮治疗阵发性室上性心动过速(PSVT)的疗效与安全性。方法:选择本院2013年1月～2018年5月收治的90例PSVT患者纳入本次研究。患者被随机均分为普罗帕酮组和胺碘酮组,两组均在常规治疗基础上接受相应药物治疗24h。观察比较两组患者治疗前后的血压水平、心率、心功能指标:LVEDV、LVESV和LVEF,对比两组的转复时间、60min内转复成功率以及治疗期间两组不良反应发生情况。结果:两组PSVT转复率(普罗帕酮组91.11%比胺碘酮组93.33%)无显著差异(P=1.000)。与治疗前比较,治疗24h后两组血压水平、心率均显著降低,P均=0.001;但治疗前后两组间均无显著差异,P均>0.05。普罗帕酮组转复时间[(12.66±2.06)min比(22.80±2.28)min]显著短于胺碘酮组,P=0.001。与普罗帕酮组比较,胺碘酮组治疗24h后LVEF显著升高[(63.24±3.67)%比(66.83±4.01)%],LVEDV显著降低[(96.65±5.24)ml比(92.09±4.37)ml],LVESV显著降低[(38.40±2.87)ml比(30.13±7.34)ml],P均=0.001。胺碘酮组不良反应总发生率(8.89%比24.44%)显著低于普罗帕酮组,P=0.048。结论:普罗帕酮与胺碘酮治疗阵发性室上性心动过速均具有显著疗效,普罗帕酮转复时间短,胺碘酮不良反应少且可提高心功能水平,临床上应根据患者的具体情况选择应用药物。
Objective: To compare therapeutic effect of propafenone and amiodarone on paroxysmal supraventricular tachycardia (PSVT) and their safety. Methods: A total of 90 PSVT patients, who were treated in our hospital from Jan 2013 to May 2018, were selected. Patients were randomly and equally divided into propafenone group and amiodarone group, each group received corresponding medication based on routine treatment for 24h. Blood pressure, heart rate, cardiac function indexes: LVEDV, LVESV and LVEF before and after treatment, cardioversion time, successful cardioversion rate within 60 min and incidence of adverse reactions during treatment were observed and compared between two groups. Results: There was no significant difference in successful cardioversion rate(propafenone group 91.11% vs. amiodarone group 93.33%, P =1.000)between two groups. Compared with before treatment, on 24h after treatment, there were significant reductions in blood pressure and heart rate in two groups, P =0.001 all;but there was no significant difference between two groups before and after treatment, P >0.05 all. Cardioversion time of propafenone group was significantly shorter than that of amiodarone group [(12.66±2.06)min vs.(22.80±2.28)min], P =0.001.Compared with propafenone group on 24h after treatment,there was significant rise in LVEF[(63.24±3.67)% vs.(66.83±4.01)%], significant reductions in LVEDV[(96.65±5.24)ml vs.(92.09±4.37)ml]and LVESV[(38.40±2.87)ml vs.(30.13±7.34)ml]in amiodarone group, P =0.001 all. Total incidence rate of adverse reactions in amiodarone group was significantly lower than that of propafenone group (8.89% vs. 24.44%), P =0.048. Conclusion: Propafenone and amiodarone possess significant therapeutic effect on PSVT. Propafenone possesses shorter cardioversion time, while amiodarone possesses less adverse reactions and improve cardiac function. Therefore, medication should be selected properly according to patient′s specific condition in clinic.
作者
钱碧云
陈良川
王明伟
郑元喜
乔锐
QIAN Bi-yun;CHEN Liang-chuan;WANG Ming-wei;ZHENG Yuan-xi;QIAO Rui(Department of Cardiology, Affiliated Anqing Hospital of Anhui Medical University, Anqing, Anhui, 246003, China)
出处
《心血管康复医学杂志》
CAS
2019年第2期221-224,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心动过速
室上性
胺碘酮
普罗帕酮
Tachycardia, supraventricular
Amiodarone
Propafenone
